Diane Dragaud

June 28, 2022

Ongoing Trial: As the TMIST breast cancer screening trial passes the halfway mark, leaders continue efforts to recruit women from diverse backgrounds

Reaching more women in local communities, especially women of color, will ensure that the trial results apply to all women—and move health equity forward
June 28, 2022

Trial Results: ECOG-ACRIN Research Round-Up – Summer 2022

Summaries of recently reported ECOG-ACRIN research results
October 2, 2020

Ongoing Trial: In the TMIST mammography trial, nearly 20% of the volunteers are Black women, thanks to a successful recruitment strategy

The TMIST breast cancer screening trial continues to enroll women during the COVID-19 pandemic. This article describes ways trial leaders and clinical staff are making TMIST available to women in minority communities.
October 2, 2020

Trial Results: For women with breast cancer in the TAILORx trial, cognitive decline from chemo was early and abrupt but did not get worse over time. Cognition also declined in the group on hormone therapy alone.

Cognitive loss—or ‘brain fog’—involves memory problems, a lack of mental clarity, and difficulty keeping one’s focus. Cancer-related brain fog is common during treatment. This study dispels the idea that it is only from chemotherapy.